The study volunteers all had their tumors removed. Researchers were able to analyze their cells for neoantigens that were specific to each melanoma and create a 'personalized' vaccine for each patient. MORE VACCINE DEVELOPMENTS: After 8 Years of Research World-Changing Malaria Vaccine Approved in Africa The vaccine took about six to eight weeks to develop for each patient and could recognize as many as 34 separate neoantigens. Severe side effects were similar between the two arms of the study, they said, with fatigue being the most common side effect specific to the vaccine reported by patients. SHARE The News Of This Potential Life-Saving Drug On Social Media…